EUCTR2019-004935-22-NL进行中（未招募）1 期
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia - OCEA
ewAmsterdam Pharma BV0 个研究点目标入组 152 人开始时间: 2020年7月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Understanding of the study procedures, willingness to adhere to the study schedules and diet, and agreement to participate in the study by giving written informed consent prior to Screening procedures;
- •2. Men or women 18 to 70 years of age, inclusive;
- •oWomen may be enrolled if all 3 of the following criteria are met:
- •?-They are not pregnant;
- •?-They are not breastfeeding; and
- •?-They do not plan on becoming pregnant during the study;
- •oWomen of childbearing potential must have a negative urine pregnancy test at the Screening Visit. Note: Women are not considered to be of childbearing potential if they meet 1 of the following criteria as documented by the Investigator:
- •?-They have had a hysterectomy or tubal ligation at a minimum of 1 cycle prior to signing the ICF; or
- •?-They are post-menopausal, defined as 1 year since their last menstrual period for women 55 years of age or 1 year since their last menstrual period and have a follicle stimulating hormone (FSH) level in the menopausal range for women <55 years of age;
- •oWomen of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit. Men whose partners are of childbearing potential must agree to use an effective method of avoiding pregnancy from the Screening Visit to 90 days after the last visit. Effective methods of avoiding pregnancy are contraceptive methods with a Pearl index of <1 used consistently and correctly (including implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, diaphragm with spermicide, male or female condoms with spermicide, or cervical cap) or a sterile sexual partner;
- •3.Fasting LDL-C levels >2.5 mmol/L and <4.5 mmol/L and TG levels <4.5 mmol/L (Visit 1); and
- •4.Willingness to maintain a stable diet and physical activity level throughout the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 127
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •1.Body mass index ?40 kg/m2;
- •2.Participation in another clinical study involving an investigational or marketed drug within 30 days prior to the Screening Visit;
- •3.Currently taking any lipid-altering therapy;
- •4.Any clinical manifestation of atherosclerotic CVD or any evidence of ischemic coronary disease present on the 12-lead ECG at the Screening Visit;
- •5.Diagnosis of type 1 or type 2 diabetes mellitus; or glycosylated hemoglobin (HbA1c) ?6.5% at the Screening Visit if no prior diagnosis of diabetes mellitus;
- •6.Uncontrolled hypertension, ie, sitting systolic blood pressure >160 mmHg and/or sitting diastolic blood pressure >90 mmHg. One retest will be allowed, at which point if the retest result is no longer exclusionary, the participant may be randomized;
- •7.Active muscle disease or persistent creatine kinase concentration >3 ? the upper limit of normal (ULN). One retest will be allowed after 1 week to verify the result, at which point if the retest result is no longer exclusionary, the participant may be randomized;
- •8.History of torsades de pointes;
- •9.Estimated glomerular filtration rate <60 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation;
- •10.Hepatic dysfunction as evidenced by any laboratory abnormality as follows: gamma-glutamyl transferase, alanine aminotransferase, or aspartate aminotransferase >2 ? ULN, or total bilirubin >1.5 ? ULN;
- •11.Anemia, defined as hemoglobin concentration <11 g/dL for males and hemoglobin concentration <9 g/dL for females;
- •12.History of malignancy within the past 5 years, with the exception of non-melanoma skin cancers;
- •13.Evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study; or
- •14.Known ezetimibe or CETP inhibitor allergy or intolerance.
研究者
相似试验
已完成
3 期
A Study of Ipatasertib in Combination with Paclitaxel as aTreatment for Participants With PIK3CA/AKT1/PTEN-Altered, locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerBreast cancerJPRN-jRCT2080223714CHUGAI PHARMACEUTICAL CO., LTD.450
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN).MedDRA version: 20.0Level: PTClassification code 10077827Term: C3 glomerulopathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-001821-42-ESChemoCentryx, Inc.44
进行中（未招募）
不适用
A study to evaluate the safety and efficacy of Blisibimod in IgA NephropathyIgA NephropathyMedDRA version: 17.1Level: PTClassification code 10021263Term: IgA nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2014-001365-26-ITAnthera pharmaceuticals, Inc200
进行中（未招募）
不适用
The study is designed to determine the safety and efficacy of progesterone in patients with severe head injurySevere traumatic brain injuryMedDRA version: 16.0Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863EUCTR2010-018283-16-NLBHR Pharma, LLC1,180
进行中（未招募）
1 期
A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host diseaseMale or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHDMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disordersEUCTR2017-000538-78-GBIncyte Corporation436